Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
In Business 33 Years - Since 1980		THE CURRENT TIME at LC Labs is:
		Search:  Product Pages Only  Entire Site

V-7300 Vinblastine, Sulfate Salt, >98%      NEW!

Synonyms:  [29060-LE] [Nincaluicolflastine] [Vinblastine hydrogen sulfate] [Vincaleucoblastine sulfate] [VLB sulfate] [29060 LE] [29060LE]
Related Terms:  [Alkaban-AQ] [Exal] [Rozevin sulfate] [Velban] [Velsar] [Velbe]

M.W. 909.05

C46H58N4O9•H2SO4

[143-67-9]

M.I. 14:  9982

Storage:  Store at or below -20 ºC.  Solubility:  Poorly soluble in ethanol; soluble in water at 50 mg/mL; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

Find and View a Certificate of Analysis for this product

View the MSDS for this product

• Vinblastine is an antimicrotubule drug that has been used to treat various cancers.  Interruption of microtubule structure by antimicrotubule drugs results in induction of tumor suppressor gene p53 and inhibitor of cyclin-dependent kinases p21WAF1/CIP1, and phosphorylation of Bcl-2, which lead to apoptosis in cancer cells.  Wang, L.G., et al.  "The effect of antimicrotubule agents on signal transduction pathways of apoptosis:  a review."  Cancer Chemother. Pharmacol. 44:  355-361 (1999).

• Combination chemotherapy with Adriamycin (doxorubicin, please see Cat. No. D-4000, Doxorubicin, Hydrochloride Salt and Cat. No. D-4099, Doxorubicin, Free Base), bleomycin, vinblastine, and dacarbazine (ABVD) is considered the standard of treatment for advanced Hodgkin's lymphoma in North America, providing a good balance of efficacy and toxicity.  Hoskin, P.J., et al.  "Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma:  United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244."  J. Clin. Oncol. 27:  5390-5396 (2009).

• Vinblastine chemotherapy is the standard treatment for the patients with aggressive systemic Langerhans cell histiocytosis.  Gadner, H., et al.  "A randomized trial of treatment for multisystem Langerhans' cell histiocytosis."  J. Pediatr. 138:  728-734 (2001).

• Vinblastine has potent anti-angiogenic properties at picomolar concentrations.  The doses of vinblastine needed to cause antiangiogenesis are significantly lower than cytotoxic doses.  Vacca, A., et al.  "Antiangiogenesis is produced by nontoxic doses of vinblastine."  Blood 94:  4143-4155 (1999).

• Co-targeting of mTOR by temsirolimus (please see Cat. No. T-8040, Temsirolimus) and microtubules by vinblastine in vitro resulted in marked growth inhibition in Huh7 cells and Hep3B cells.  The combination of temsirolimus and vinblastine induced a significant and sustained antitumor activity in both Huh7 and Hep3B xenograft models, with significant reduction of tumor vessel density.  Zhou, Q., et al.  "Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma."  Biochem. Pharmacol. 83:  1146-1158 (2012).

• Weekly vinblastine was demonstrated to be a reasonable alternative to radiation for pediatric patients with low-grade glioma who had failed first-line chemotherapy.  The 5-year progression-free survival was shown in this phase II trial to be comparable to results observed with first-line chemotherapy in chemotherapy-naive patients.  Bouffet, E., et al.  "Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma."  J. Clin. Oncol. 30:  1358-1363 (2012).

• Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin appeared to be a safe, well-tolerated, and effective neoadjuvant chemotherapy regimen for muscle-invasive bladder cancer.  Blick, C., et al.  "Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder."  Cancer 118:  3920-3927 (2012).

• Related CAS number:  865-21-4 for the free base.

• STRUCTURE ERRORS ON WIKIPEDIA AND TWO VENDORS' WEBSITES:  As of December 21, 2012, the vinblastine structures shown on Wikipedia and at least two vendors' (Santa Cruz and Sigma) web pages are incorrect in one or more ways.  (We have not checked most other vendors' vinblastine structures.)  Also, the vinblastine structure shown on Chemblink fails to specify the stereochemistry at one asymmetric carbon atom.  Finally, the Merck Index Vol. 14 entry for vinblastine shows a dashed bond connecting a nitrogen atom and a symmetrically substituted carbon atom; this appears to be a bond that would not normally be shown as embodying stereochemical information, so our structure shows it as a plain single bond.

• Vinblastine is the active ingredient in drug products sold under numerous trade names, such as those listed near the top of this page as "Related Terms".  These drug products have been approved in at least one country for use in patients with cancer.  NOTE:  THE VINBLASTINE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT ANY OF THE VINBLASTINE-CONTAINING DRUG PRODUCTS SOLD UNDER VARIOUS TRADE NAMES AND IS NOT FOR HUMAN USE.

• Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.

** Our prices are lower than other vendors', but there is no compromise in quality.  Read how we are able to accomplish this:  Product Quality Discussion.

NOTES:
1.  The purpose of our competitor price comparison tables is to enable our visitors to compare the prices and purities of products of nominally equivalent quality, for vendors whose price and purity claims are openly available from a website or catalog (without a need for the customer to contact the vendor and request a quotation in order to obtain a price and purity for a standard product size).  However, the quality comparisons in these tables are not absolute:  although our product purities are uniformly very high and are established by careful testing of every lot in our laboratories, we cannot and do not vouch for the purities claimed by other vendors in these competitor price comparison tables.  (We do carry out occasional testing of other vendors' products -- see below --  and we have found many instances where vendors' product purities are far below their claimed levels.)  Effective April 1, 2011, our price comparison tables only include products where a purity commitment is found together with sizes and prices on at least one page of the vendor's web site.

2.  Researching and compiling sizes and prices for the >160 competitive vendors and more than 175 products is an expensive and tedious task for our small company.  Thus, we typically only perform revisions of these tables annually or less frequently.  The date and source of each competitive vendor's prices is indicated at the bottom of this page.  Obviously, we make no guarantee that competitive vendor prices will remain unchanged in the interval between our annual revisions.  We may occasionally update individual competitive vendor information and add new competitive vendors as we locate them.

3.  In some circumstances we permanently remove vendors from our price comparison tables.  Circumstances that lead to permanent removal are: 

A.  If a vendor does not honor its advertised price (ignoring small price increases) for one or more products when an order is attempted.  Example:  a vendor listed a compound at $808 for 10 grams on its website price list, but quoted $4,500 per 10 grams upon our inquiry.  That vendor has been permanently removed from our price comparison tables.

B.  If, on a product-by-product basis, our analyses of a vendor's product show purities more than a few percent below the vendor's advertised purities.  Example:  a vendor advertises a purity for 97% for a compound, but repeated elemental analyses show a minimum of 9% inorganic material present, beyond any salt counterion.  Another example: an HPLC analysis at a relevant UV detector wavelength shows 92% purity for a vendor's product for which 98% purity is claimed.  We realize of course that UV absorbances for impurities can be higher than for the main compound, but our products meet our purity commitment of typically >99% irrespective of absorbance factors for impurities, and we apply that standard to products from other vendors.

C.  Again on a product-by-product basis, if a vendor makes no purity claim for a given product, then their product is not shown on that product table.

D.  If we find that, as a pattern, several of a competitive vendor's products fail to meet their advertised purity commitments by significant margins or if a vendor does not provide standard and consistent purity claims for several of its products, then that vendor is permanently removed from all of our competitor price tables.

E.  Finally, if we determine that a vendor has provided fraudulent information on its website, in its literature or on a certificate of analysis, that vendor is permanently removed from all of our price comparison tables.

4.  IMPORTANT:  The presence of a competitive vendor entry in our price comparison tables does not necessarily mean that we have analyzed any of that vendor's products for purity; indeed, in most cases we have not.

5.  Please note:  where necessary, competitor prices are rounded to the nearest whole dollar.

To the best of our knowledge, the prices listed above for our competitors' products were correct as of the dates listed below for the sources of our annual price information update process.

Pricing Sources and Dates:  LC Labs - Current, Sigma-Aldrich - website - Jan 2013, Enzo Life Sciences - website - Jan 2013, Tocris Bioscience - website - Jan 2013, AG Scientific - website - Jan 2013, AntibioticPlus - website - Jan 2013, Axxora - website - Jan 2013, LKT Labs - website - May 2013, Wako Chemicals - website - Jan 2013, Lab Depot - website - Jan 2013, Science Lab - website - Jan 2013, Santa Cruz Biotech - website - Jan 2013, Cayman Chemical - website - Apr 2013, Acros Organics - website - Jan 2013, Cole-Parmer - website - Jan 2013, PGC Scientifics - website - Jan 2013, BioVision - website - Jan 2013, R&D Systems - website - Jan 2013, Colonial Scientific - website - Jan 2013, AK Scientific - website - Mar 2013, Neobits - website - Mar 2013, Alfa Aesar - website - Mar 2013, Cambridge BioScience - website - Oct 2012, Carbone Scientific - website - Jan 2013, JIT Lab Supply - website - Jan 2013, J&K Scientific - website - Jan 2013, TCASChem Tech - website - Apr 2013, antibodies-online - website - Jan 2013, biorbyt.com - website - Jan 2013, Utech Products - website - Sep 2012, Abblis Chemicals - website - Jan 2013, P212121 - website - Jan 2013, Biopurify Phytochemicals - website - Jan 2013, Cherry Instruments - website - Jan 2013, AOKBIO - website - May 2013, MedKoo BioSciences - website - Apr 2013, Krackeler Scientific - website - Jan 2013, LabLife - website - Jan 2013, VIVA Bioscience - website - Jan 2013, Reagent World - website - Dec 2012, Sapphire North America - website - Apr 2013.